Esperion Therapeutics Future Growth
Future criteria checks 5/6
Esperion Therapeutics is forecast to grow earnings and revenue by 64.2% and 29.8% per annum respectively while EPS is expected to grow by 66% per annum.
Key information
64.2%
Earnings growth rate
66.0%
EPS growth rate
| Pharmaceuticals earnings growth | 16.3% |
| Revenue growth rate | 29.8% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 06 Sep 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 550 | 139 | N/A | N/A | 4 |
| 12/31/2025 | 420 | 58 | 142 | 58 | 6 |
| 12/31/2024 | 343 | -27 | 93 | 28 | 7 |
| 6/30/2024 | 278 | -98 | -10 | -10 | N/A |
| 3/31/2024 | 230 | -87 | -27 | -27 | N/A |
| 12/31/2023 | 116 | -209 | -135 | -135 | N/A |
| 9/30/2023 | 103 | -208 | -141 | -141 | N/A |
| 6/30/2023 | 88 | -222 | -164 | -164 | N/A |
| 3/31/2023 | 81 | -239 | -190 | -190 | N/A |
| 12/31/2022 | 75 | -234 | -175 | -175 | N/A |
| 9/30/2022 | 72 | -243 | -190 | -190 | N/A |
| 6/30/2022 | 67 | -258 | -216 | -216 | N/A |
| 3/31/2022 | 89 | -235 | -214 | -214 | N/A |
| 12/31/2021 | 78 | -269 | -264 | -264 | N/A |
| 9/30/2021 | 73 | -308 | -287 | -275 | N/A |
| 6/30/2021 | 62 | -325 | -305 | -292 | N/A |
| 3/31/2021 | 234 | -156 | -118 | -105 | N/A |
| 12/31/2020 | 228 | -144 | -99 | -85 | N/A |
| 9/30/2020 | 219 | -101 | -67 | -67 | N/A |
| 6/30/2020 | 216 | -84 | -39 | -38 | N/A |
| 3/31/2020 | 5 | -263 | -232 | -231 | N/A |
| 12/31/2019 | 148 | -97 | -71 | -70 | N/A |
| 9/30/2019 | 147 | -95 | -50 | -49 | N/A |
| 6/30/2019 | 146 | -77 | -29 | -29 | N/A |
| 3/31/2019 | 145 | -68 | -14 | -14 | N/A |
| 12/31/2018 | N/A | -202 | -149 | -149 | N/A |
| 9/30/2018 | N/A | -180 | -155 | -155 | N/A |
| 6/30/2018 | N/A | -175 | -153 | -153 | N/A |
| 3/31/2018 | N/A | -173 | N/A | -140 | N/A |
| 12/31/2017 | N/A | -167 | N/A | -131 | N/A |
| 9/30/2017 | N/A | -158 | N/A | -113 | N/A |
| 6/30/2017 | N/A | -130 | N/A | -91 | N/A |
| 3/31/2017 | N/A | -101 | N/A | -72 | N/A |
| 12/31/2016 | N/A | -75 | N/A | -48 | N/A |
| 9/30/2016 | N/A | -59 | N/A | -40 | N/A |
| 6/30/2016 | N/A | -55 | N/A | -37 | N/A |
| 3/31/2016 | N/A | -53 | N/A | -39 | N/A |
| 12/31/2015 | N/A | -50 | N/A | -38 | N/A |
| 9/30/2015 | N/A | -46 | N/A | -38 | N/A |
| 6/30/2015 | N/A | -43 | N/A | -35 | N/A |
| 3/31/2015 | N/A | -40 | N/A | -32 | N/A |
| 12/31/2014 | N/A | -36 | N/A | -32 | N/A |
| 9/30/2014 | N/A | -37 | N/A | -31 | N/A |
| 6/30/2014 | N/A | -32 | N/A | -27 | N/A |
| 3/31/2014 | N/A | -30 | N/A | -25 | N/A |
| 12/31/2013 | N/A | -26 | N/A | -18 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0IIM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: 0IIM is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 0IIM is expected to become profitable in the next 3 years.
Revenue vs Market: 0IIM's revenue (29.8% per year) is forecast to grow faster than the UK market (3.7% per year).
High Growth Revenue: 0IIM's revenue (29.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 0IIM's Return on Equity is forecast to be high in 3 years time